المؤلفون: Soria, Angele, Amsler, Emmanuelle, Bernier, Claire, Milpied, Brigitte, Tetart, Florence, Morice, Cecile, Dezoteux, Frédéric, Ferrier-Le Bouedec, Marie-Christine, Barbaud, Annick, staumont, delphine, Assier, Haudrey

المساهمون: CHU Lille, Inserm, Université de Lille, Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

الوصف: BACKGROUND: Drug reactions with eosinophilia and systemic symptoms (DRESSs) and acute generalized exanthematous pustulosis (AGEP) are potentially severe cutaneous adverse drug reactions. OBJECTIVE: To describe the clinical findings and sensitization profiles of DRESS and AGEP patients who had been administered iodinated contrast media (ICM). METHODS: All adult patients in the dermatologist's French Investigators for Skin Adverse Reactions to Drugs (FISARD) network diagnosed with a DRESS or AGEP highly suspected to have been caused by an ICM were included retrospectively. RESULTS: Thirteen DRESS patients and 19 AGEP patients who had been administered ICM were included, and the median delay in DRESS and AGEP occurrence after ICM administration was short, 4 and 1 days, respectively. Five AGEP patients had systemic involvement. A high cosensitization rate (46%) was observed among the DRESS patients, mainly with beta-lactam antibiotics. Overall, 77% of our patients were sensitized to several ICM. Patch tests identified the suspected ICM for 21 cases (72%). The retrospective nature, the limited number of subjects, the absence of a control group of healthy individuals, and the lack of detailed information on previous exposure to sensitizing drugs are limitations of this study. CONCLUSIONS: We report a large series of DRESSs and AGEPs related to ICM administration. Skin tests appear useful for diagnosis and potentially to identify alternative ICM. ; 9

وصف الملف: application/octet-stream

العلاقة: The Journal of Allergy and Clinical Immunology: In Practice; J Allergy Clin Immunol Pract; http://hdl.handle.net/20.500.12210/40490Test

الإتاحة: https://doi.org/20.500.12210/40490Test
https://hdl.handle.net/20.500.12210/40490Test

المؤلفون: Bocquel, Sarah, Soria, Angèle, Raison-Peyron, Nadia, Badaoui, Antoine, Marcant, Pierre, Bara, Corina, Giordano-Labadie, Françoise, Amsler, Emmanuelle, Milpied, Brigitte, Delaunay, Juliette, Darrigade, Anne-Sophie, Pralong, Pauline, Boulard, Claire, Ferrier Le Bouedec, Marie-Christine, Tauber, Marie, Pasteur, Justine, Valois, Aude, Le Thuaut, Aurélie, Crépy, Marie-Noëlle, Bernier, Claire

المصدر: Journal of the American Academy of Dermatology ; volume 90, issue 3, page 512-520 ; ISSN 0190-9622

مصطلحات موضوعية: Dermatology

الإتاحة: https://doi.org/10.1016/j.jaad.2023.10.029Test
https://api.elsevier.com/content/article/PII:S0190962223030323?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0190962223030323?httpAccept=text/plainTest

المؤلفون: Goujon, Catherine, Viguier, Manuelle, Staumont, delphine, Bernier, Claire, Guillet, Gerard, Lahfa, Morad, Ferrier Le Bouedec, Marie-Christine, Cambazard, Frederic, Bottigioli, David, Grande, Sophie, Dahel, Karima, Berard, Frederic, Rabilloud, Muriel, Mercier, Catherine, Nicolas, Jean-Francois

المساهمون: Service d'immunologie Centre Hospitalier Lyon Sud - HCL, Immuno-Régulation dans les Maladies Auto-Immunes Inflammatoires et le Cancer - EA 7509 IRMAIC, Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (EGID) - U1011, Service de dermatologie Nantes, Laboratoire Inflammation, Tissus épithéliaux et Cytokines LITEC Poitiers, Service Dermatologie CHU Toulouse, Service de Dermatologie et Oncologie Cutanée CHU Clermont-Ferrand, Service de Dermatologie CHU Saint-Etienne, Centre Hospitalier Lyon Sud CHU - HCL CHLS, Biostatistiques santé

مصطلحات موضوعية: Cyclosporine, Atopic dermatitis, Methotrexate, Trial

الوصف: Methotrexate is currently used to treat atopic dermatitis but has never been assessed versus cyclosporine in adults. This study evaluated the efficacy and safety of methotrexate versus cyclosporine in patients with moderate-to-severe atopic dermatitis. Patients were randomized to receive either oral methotrexate (15 mg/wk) or cyclosporine (2.5 mg/kg/d) for 8 weeks. The primary end point was a patient achieving 50% improvement in the SCORing Atopic Dermatitis index (SCORAD 50) at week 8. When the primary end point was not achieved, methotrexate was increased to 25 mg and cyclosporine to 5 mg during the next 16 weeks. The secondary end points were a patient achieving a 50% reduction in the Eczema Area Severity Intensity index (EASI 50) and SCORAD 50 at each visit (ClinicalTrials.gov no. NCT00809172). A total of 97 patients received methotrexate 15 mg (n = 50) or cyclosporine 2.5 mg (n = 47). Regarding the primary end point at week 8, methotrexate was inferior to cyclosporine because the proportion of patients with SCORAD 50 was 8% (4 of 50) in the methotrexate arm versus 42% (18 of 43) in the cyclosporine arm. The difference in percentages for the 2 treatment groups (2-sided 90% CI) was -34% (-48% to -20%). At week 8, methotrexate and cyclosporine dosages were increased in 56% and 49% of the patients, respectively. Regarding EASI 50, the noninferiority end point was reached at week 20 in 92% (22 of 24) of patients in the methotrexate arm and 87% (26 of 30) of patients in the cyclosporine arm. The treatment-related adverse events were more frequent with cyclosporine (P < .0001). Methotrexate 15 mg/wk was inferior to cyclosporine 2.5 mg/kg/d at week 8. Increasing the doses of methotrexate to 25 mg/wk induced a significant improvement versus cyclosporine at week 20. ; 6

العلاقة: The Journal of Allergy and Clinical Immunology: In Practice; J. Allergy Clin. Immunol.-Pract.; http://hdl.handle.net/20.500.12210/104890Test

الإتاحة: https://doi.org/20.500.12210/104890Test
https://hdl.handle.net/20.500.12210/104890Test

المؤلفون: Faiz, Sarah, Giovannelli, Jonathan, Podevin, Celine, Jachiet, Marie, Bouaziz, Jean-David, Reguiai, Ziad, Nosbaum, Audrey, Lasek, Audrey, Ferrier Le Bouedec, Marie-Christine, Du Thanh, Aurelie, Raison-Peyron, Nadia, Tetart, Florence, Duval-Modeste, Anne-Benedicte, Misery, Laurent, Aubin, Francois, Dompmartin, Anne, Morice, Cecile, Droitcourt, Catherine, Soria, Angele, Arnault, Jean-Philippe, Delaunay, Juliette, Mahe, Emmanuel, Richard, Marie-Aleth, Schoeffler, Amelie, Lacour, Jean-Philippe, Begon, Edouard, Walter-Lepage, Amelie, Dillies, Anne-Sophie, Rappelle-Duruy, Sandrine, Barete, Stephane, Bellon, Nathalia, Beneton, Nathalie, Valois, Aude, Barbarot, Sebastien, Seneschal, Julien, staumont, delphine

المساهمون: CHU Lille, Inserm, Université de Lille, Lille Inflammation Research International Center (LIRIC) - U995, Lille Inflammation Research International Center - U 995 LIRIC, Université Paris Diderot - Paris 7 UPD7, Université Claude Bernard Lyon 1 UCBL, Université de Clermont-Ferrand, Université de Montpellier UM, Université de Franche-Comté UFC, Université de Rennes UR, Sorbonne Université SU, Aix Marseille Université AMU, Sorbonne Universités (COMUE), Université de Bordeaux UB

الوصف: BACKGROUND: Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials. OBJECTIVE: We sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort. METHODS: We included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up. RESULTS: We included 241 patients. The median ± interquartile range (IQR) follow-up time was 3.8 ± 3.7 months. A ≥75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a ≥75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD ± IQR, 25 ± 21 vs 56 ± 27.4, P < 10 and EASI ± IQR, 4.1 ± 6.8 vs 17.9 ± 15.4, P < 10 , respectively). Conjunctivitis was reported in 84 of 241 (38.2%) patients. The proportion with eosinophilia (>500 cells/mm ) during follow-up (57%) was higher than that at baseline (33.7%) (n = 172, P < 10 ). Dupilumab was stopped in 42 cases; 27 patients stopped because of AEs. CONCLUSIONS: No control group, missing data. CONCLUSIONS: This real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a higher frequency of conjunctivitis and eosinophilia. ; 81

العلاقة: Journal of The American Academy of Dermatology; J. Am. Acad. Dermatol.; http://hdl.handle.net/20.500.12210/13774Test

الإتاحة: https://doi.org/20.500.12210/13774Test
https://hdl.handle.net/20.500.12210/13774Test

المؤلفون: Costedoat, Ingrid, Wallaert, Martin, Gaultier, Aurélie, Vasseur, Robin, Vanhaecke, Clelia, Viguier, Manuelle, Cordelette, Charles, Denoyer, Alexandre, Ferrier Le Bouëdec, Marie-Christine, Coutu, Adrien, Lamiaux, Marie, Tran, Thi-Ha-Chau, Lacour, Jean-Philippe, Elmaleh, Valerie, Tetart, Florence, Gueudry, Julie, Tauber, Marie, Giordano-Labadie, Françoise, Cassagne, Myriam, Nosbaum, Audrey, Ouilhon, Coralie, Jachiet, Marie, Tadayoni, Ramin, Dezoteux, Frédéric, Staumont, delphine, Bouleau, Julien, Labalette, Pierre, Doan, Serge, Soria, Angele, Mortemousque, Bruno, Seneschal, Julien, Barbarot, Sebastien

المساهمون: Université de Lille, Inserm, CHU Lille, CHU Bordeaux, Centre Hospitalier Universitaire de Nantes CHU Nantes, Hôpital universitaire Robert Debré Reims, CHU Clermont-Ferrand, Université catholique de Lille UCL, Centre Hospitalier Universitaire de Nice CHU Nice, CHU Rouen, Centre Hospitalier Universitaire de Toulouse CHU Toulouse, Hospices Civils de Lyon HCL, Centre International de Recherche en Infectiologie CIRI, Centre Hospitalier Lyon Sud CHU - HCL CHLS, Hopital Saint-Louis AP-HP AP-HP, Hôpital Lariboisière-Fernand-Widal APHP, Institute for Translational Research in Inflammation - U 1286 INFINITE (Ex-Liric), Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286, Centre Hospitalier Régional Universitaire CHU Lille CHRU Lille, CHU Tenon AP-HP

الوصف: Background Although ocular adverse events are frequent in AD patients treated with dupilumab, their characterization remains limited due to a lack of prospective studies with a systematic ophthalmological examination. Objective To examine the incidence, characteristics and risk factors of dupilumab-induced ocular adverse events. Methods A prospective, multicenter, and real-life study in adult AD patients treated with dupilumab. Results At baseline, 27 out of 181 patients (14.9%) had conjunctivitis. At week 16 (W16), 25 out of 27 had improved their conjunctivitis and 2 remained stable and 34 out of 181 patients (18.7%) had dupilumab-induced blepharoconjunctivitis: either de novo (n = 32) or worsening of underlying blepharoconjunctivitis (n = 2). Most events (27/34; 79.4%) were moderate. A multivariate analysis showed that head and neck AD (OR = 7.254; 95%CI [1.938–30.07]; p = 0.004), erythroderma (OR = 5.635; 95%CI [1.635–21.50]; p = 0.007) and the presence of dry eye syndrome at baseline (OR = 3.51; 95%CI [3.158–13.90]; p = 0.031) were independent factors associated with dupilumab-induced blepharoconjunctivitis. Limitations Our follow-up period was 16 weeks and some late-onset time effects may still occur. Conclusion This study showed that most dupilumab-induced blepharoconjunctivitis cases are de novo. AD severity and conjunctivitis at baseline were not found to be associated risk factors in this study.

العلاقة: Journal of the European Academy of Dermatology and Venereology; J Eur Acad Dermatol Venereol; http://hdl.handle.net/20.500.12210/100638Test

الإتاحة: https://doi.org/20.500.12210/100638Test
https://hdl.handle.net/20.500.12210/100638Test

المؤلفون: Soria, Angèle, Amsler, Emmanuelle, Bernier, Claire, Milpied, Brigitte, Tétart, Florence, Morice, Cécile, Dezoteux, Frédéric, Ferrier-Le Bouedec, Marie-Christine, Barbaud, Annick, Staumont-Sallé, Delphine, Assier, Haudrey

المساهمون: Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille)

المصدر: The Journal of Allergy and Clinical Immunology: In Practice ; https://hal.science/hal-03983346Test ; The Journal of Allergy and Clinical Immunology: In Practice, 2021, 9 (8), pp.3041-3050. ⟨10.1016/j.jaip.2021.02.060⟩

مصطلحات موضوعية: [SDV]Life Sciences [q-bio]

الوصف: International audience

العلاقة: hal-03983346; https://hal.science/hal-03983346Test; https://hal.science/hal-03983346/documentTest; https://hal.science/hal-03983346/file/S2213219821003184.pdfTest; PII: S2213-2198(21)00318-4

الإتاحة: https://doi.org/10.1016/j.jaip.2021.02.060Test
https://hal.science/hal-03983346Test
https://hal.science/hal-03983346/documentTest
https://hal.science/hal-03983346/file/S2213219821003184.pdfTest

المؤلفون: Clément, Aude¹ (AUTHOR) aclement1@chu-clermontferrand.fr, Ferrier le Bouëdec, Marie‐Christine¹ (AUTHOR), Crépy, Marie‐Noëlle² (AUTHOR), Raison‐Peyron, Nadia³ (AUTHOR), Tétart, Florence⁴ (AUTHOR), Marcant, Pierre⁵ (AUTHOR), Pralong, Pauline⁶ (AUTHOR), Valois, Aude⁷ (AUTHOR), Pasteur, Justine¹ (AUTHOR), Assier, Haudrey⁸ (AUTHOR), Bernier, Claire⁹ (AUTHOR), Le Cam, Marie‐Thérèse¹⁰ (AUTHOR), Hacard, Florence¹¹ (AUTHOR), Nosbaum, Audrey¹¹ (AUTHOR), Giordano Labadie, Françoise¹² (AUTHOR), Morice, Cécile¹³ (AUTHOR), Leleu, Camille¹⁴ (AUTHOR), Milpied, Brigitte¹⁵ (AUTHOR), Darrigade, Anne‐Sophie¹⁵ (AUTHOR), Delaunay, Juliette¹⁶ (AUTHOR)

المصدر: Contact Dermatitis (01051873). Sep2023, Vol. 89 Issue 3, p143-152. 10p.

مصطلحات موضوعية: *ECZEMA, *CONTACT dermatitis, *POLYVINYL chloride, *ALLERGENS

مستخلص: Background: Allergic contact dermatitis to gloves is mostly induced by rubber accelerators. The European baseline series (EBS) appears insufficient to detect glove allergy. Since 2017, it is recommended to use the European rubber series (ERS) and to test the patients' own gloves. Objectives: To investigate the clinical profile of glove‐wearing patients with hand eczema (HE) and to evaluate their sensitisation profile to glove allergens and the value of testing the patients' own gloves. Methods: We conducted a French multicentre study of patients evaluated for HE between 2018 and 2020 and tested with the EBS, the ERS and their own gloves in patch tests and semi‐open (SO) tests. Results: A total of 279 patients were included; 32.6% of patients had positive tests to their own gloves or to glove allergens. Almost 45% of the sensitisations to glove allergens were detected only by the ERS. Among the patients tested both in patch tests and SO tests with their own gloves with positive results, 28% had positive SO tests only. Polyvinylchloride (PVC) gloves were positive in four patients. Conclusion: Our series confirms the need to test the ERS. All the patients' gloves must also be tested including PVC gloves. SO tests with gloves are useful as a complement to patch tests. [ABSTRACT FROM AUTHOR]

المؤلفون: Costedoat, Ingrid, Wallaert, Martin, Gaultier, Aurelie, Vasseur, Robin, Vanhaecke, Clelia, Viguier, Manuelle, Cordelette, Charles, Denoyer, Alexandre, Ferrier le Bouëdec, Marie‐Christine, Coutu, Adrien, Lamiaux, Marie, Tran, Thi Ha Châu, Lacour, Jean Philippe, Elmaleh, Valerie, Tetart, Florence, Gueudry, Julie, Tauber, Marie, Giordano‐Labadie, Francoise, Cassagne, Myriam, Nosbaum, Audrey, Ouilhon, Coralie, Jachiet, Marie, Tadayoni, Ramin, Dezoteux, Frederic, Staumont‐Salle, Delphine, Bouleau, Julien, Labalette, Pierre, Doan, Serge, Soria, Angele, Mortemousque, Bruno, Seneschal, Julien, Barbarot, Sebastien

المصدر: Journal of the European Academy of Dermatology and Venereology ; volume 37, issue 5, page 1056-1063 ; ISSN 0926-9959 1468-3083

الوصف: Background Although ocular adverse events are frequent in AD patients treated with dupilumab, their characterization remains limited due to a lack of prospective studies with a systematic ophthalmological examination. Objective To examine the incidence, characteristics and risk factors of dupilumab‐induced ocular adverse events. Methods A prospective, multicenter, and real‐life study in adult AD patients treated with dupilumab. Results At baseline, 27 out of 181 patients (14.9%) had conjunctivitis. At week 16 (W16), 25 out of 27 had improved their conjunctivitis and 2 remained stable and 34 out of 181 patients (18.7%) had dupilumab‐induced blepharoconjunctivitis: either de novo ( n = 32) or worsening of underlying blepharoconjunctivitis ( n = 2). Most events (27/34; 79.4%) were moderate. A multivariate analysis showed that head and neck AD (OR = 7.254; 95%CI [1.938–30.07]; p = 0.004), erythroderma (OR = 5.635; 95%CI [1.635–21.50]; p = 0.007) and the presence of dry eye syndrome at baseline (OR = 3.51; 95%CI [3.158–13.90]; p = 0.031) were independent factors associated with dupilumab‐induced blepharoconjunctivitis. Limitations Our follow‐up period was 16 weeks and some late‐onset time effects may still occur. Conclusion This study showed that most dupilumab‐induced blepharoconjunctivitis cases are de novo. AD severity and conjunctivitis at baseline were not found to be associated risk factors in this study.

الإتاحة: https://doi.org/10.1111/jdv.18932Test

المؤلفون: Plaquevent, Marthe, Tétart, Florence, Fardet, Laurence, Ingen-Housz-Oro, Saskia, Valeyrie-Allanore, Laurence, Bernard, Philippe, Hebert, Vivien, Roussel, Aude, Avenel-Audran, Martine, Chaby, Guillaume, D’incan, Michel, Ferrier-Le-Bouedec, Marie-Christine, Duvert-Lehembre, Sophie, Picard-Dahan, Catherine, Jeudy, Géraldine, Collet, Evelyne, Labeille, Bruno, Morice, Cécile, Richard, Marie-Aleth, Bourgault-Villada, Isabelle, Litrowski, Noémie, Bara, Corina, Mahé, Emmanuel, Prost-Squarcioni, Catherine, Alexandre, Marina, Quéreux, Gaëlle, Bernier, Claire, Soria, Angèle, Thomas-Beaulieu, Domitille, Pauwels, Christine, Dereure, Olivier, O., Benichou, Jacques, Joly, Pascal

المساهمون: CHU Rouen, Normandie Université (NU), Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de référence des maladies bulleuses autoimmunes, Hôpital Henri Mondor, Hôpital universitaire Robert Debré Reims, Centre Hospitalier Régional d'Orléans (CHRO), Université d'Angers (UA), Université de Picardie Jules Verne (UPJV), Université de Clermont-Ferrand, Université de Lille, AP-HP - Hôpital Bichat - Claude Bernard Paris, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Nanterre (UPN), Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de Dermatologie CHU Saint-Etienne, Centre Hospitalier Universitaire de Saint-Etienne CHU Saint-Etienne (CHU ST-E)-Université Jean Monnet - Saint-Étienne (UJM), Université Jean Monnet - Saint-Étienne (UJM), Université de Caen Normandie (UNICAEN), Centre de Recherches en Oncologie biologique et Oncopharmacologie (CRO2), Aix Marseille Université (AMU)-Hôpital de la Timone CHU - APHM (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Ambroise Paré AP-HP, Groupe Hospitalier du Havre Hôpital Jacques Monod (MONTIVILLIERS) (GHH), Centre Hospitalier Le Mans (CH Le Mans), Hôpital d'Argenteuil, Université Paris 13 (UP13), Université de Nantes (UN), CHU Tenon AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS Poissy, Université de Montpellier (UM), Unité de biostatistiques CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

المصدر: ISSN: 0022-202X.

مصطلحات موضوعية: [SDV.CAN]Life Sciences [q-bio]/Cancer

الوصف: International audience ; Dipeptidyl peptidase-4 inhibitors have been suspected to induce bullous pemphigoid (BP). The objective of this study was to compare the observed frequency of gliptin intake in a large sample of 1,787 BP patients diagnosed between 2012 and 2015 in France, with the expected frequency after indirect age standardization on 225,412 individuals extracted from the database of the National Healthcare Insurance Agency. The secondary objective was to assess the clinical characteristics and the course of gliptin-associated BP, depending on whether gliptin was continued or stopped. The observed frequencies of intake of the whole gliptin class and that of vildagliptin in the BP population were higher than those in the general population after age standardization (whole gliptin class: 6.0%; 95% confidence interval = 4.9-7.1% vs. 3.6%, observed-to-expected drug intake ratio = 1.7; 95% confidence interval = 1.4-2.0; P < 0.0001; vildagliptin = 3.3%; 95% confidence interval = 2.5-4.1% vs. 0.7%, ratio = 4.4; 95% confidence interval = 3.5-5.7; P < 0.0001). The association of any gliptin+metformin was also higher than in the general population, ratio = 1.8 (95% confidence interval = 1.3-2.4; P < 0.0001). Gliptin-associated BP had no specific clinical characteristics. Gliptin was stopped in 48 (45.3%) cases. Median duration to achieve disease control, rate, and delay of relapse were not different whether gliptin was stopped or continued. This study strongly supports the association between gliptin intake, particularly vildagliptin, and the onset of BP.

العلاقة: hal-02090290; https://hal.science/hal-02090290Test; https://hal.science/hal-02090290/documentTest; https://hal.science/hal-02090290/file/S0022202X18329233.pdfTest; PII: S0022-202X(18)32923-3

الإتاحة: https://doi.org/10.1016/j.jid.2018.10.045Test
https://hal.science/hal-02090290Test
https://hal.science/hal-02090290/documentTest
https://hal.science/hal-02090290/file/S0022202X18329233.pdfTest

المؤلفون: Faiz, Sarah, Giovannelli, Jonathan, Podevin, Céline, Jachiet, Marie, Bouaziz, Jean-David, Reguiai, Ziad, Nosbaum, Audrey, Lasek, Audrey, Ferrier Le Bouedec, Marie-Christine, Du Thanh, Aurélie, Raison-Peyron, Nadia, Tetart, Florence, Duval-Modeste, Anne-Benedicte, Misery, Laurent, Aubin, François, Dompmartin, Anne, Morice, Cécile, Droitcourt, Catherine, Soria, Angele, Arnault, Jean-Philippe, Delaunay, Juliette, Mahé, Emmanuel, Richard, Marie-Aleth, Schoeffler, Amélie, Lacour, Jean-Philippe, Begon, Edouard, Walter-Lepage, Amélie, Dillies, Anne-Sophie, Rappelle-Duruy, Sandrine, Barete, Stéphane, Bellon, Nathalia, Beneton, Nathalie, Valois, Aude, Barbarot, Sébastien, Sénéchal, Julien, Staumont-Sallé, Delphine

المساهمون: Service de Dermatologie, Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Lille Inflammation Research International Center - U 995 (LIRIC), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Service de Dermatologie AP-HP Hôpital Saint-Louis, Hopital Saint-Louis AP-HP (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Polyclinique Courlancy (PC), Polyclinique de Courlancy, Immunologie de l'allergie cutanée et vaccination – Immunology of skin allergy and vaccination, Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Saint Vincent de Paul de Lille, Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL), Université catholique de Lille (UCL)-Université catholique de Lille (UCL), Université de Clermont-Ferrand, Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier), Service de dermatologie Rouen, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de Dermatologie Rouen, Hôpital Charles Nicolle Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Service de dermatologie, Hôpital Augustin Morvan-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Département de dermatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté COMUE (UBFC)-Université Bourgogne Franche-Comté COMUE (UBFC), Service de Dermatologie CHU Caen, Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Dermatologie Rennes = Dermatology Rennes, Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, CHU Tenon AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service de dermatologie CHU d'Amiens-Picardie, CHU Amiens-Picardie, Département de dermatologie, CHU Angers, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de Dermatologie et pathologies vasculaires CH Argenteuil, Centre Hospitalier Victor Dupouy, Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Service de Dermatologie Nice, Hôpital Archet 2 Nice (CHU), Centre Hospitalier René Dubos Pontoise, Centre hospitalier universitaire de Poitiers = Poitiers University Hospital (CHU de Poitiers La Milétrie ), Université de Picardie Jules Verne (UPJV), Service de Dermatologie, Hôpital Joseph Imbert, Centre Hospitalier d'Arles, CHU Pitié-Salpêtrière AP-HP, Service de dermatologie CHU Necker, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Necker - Enfants Malades AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Le Mans (CH Le Mans), Hôpital d'Instruction des Armées Sainte Anne, Service de Santé des Armées, Neurofibromatosis Clinic, Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM)

المصدر: ISSN: 0190-9622.

مصطلحات موضوعية: adultsatopic dermatitis, biotherapy, conjunctivitis, dupilumab, eosinophilia, [SDV]Life Sciences [q-bio]

الوصف: International audience ; BackgroundDupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials.ObjectiveWe sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort.MethodsWe included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up.ResultsWe included 241 patients. The median ± interquartile range (IQR) follow-up time was 3.8 ± 3.7 months. A ≥75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a ≥75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD ± IQR, 25 ± 21 vs 56 ± 27.4, P < 10−9 and EASI ± IQR, 4.1 ± 6.8 vs 17.9 ± 15.4, P < 10−9, respectively). Conjunctivitis was reported in 84 of 241 (38.2%) patients. The proportion with eosinophilia (>500 cells/mm3) during follow-up (57%) was higher than that at baseline (33.7%) (n = 172, P < 10−6). Dupilumab was stopped in 42 cases; 27 patients stopped because of AEs.LimitationsNo control group, missing data.ConclusionThis real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a higher frequency of conjunctivitis and eosinophilia.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/30825533; hal-02321685; https://hal.umontpellier.fr/hal-02321685Test; https://hal.umontpellier.fr/hal-02321685/documentTest; https://hal.umontpellier.fr/hal-02321685/file/S0190962219303457.pdfTest; PII: S0190-9622(19)30345-7; PRODINRA: 483270; PUBMED: 30825533; WOS: 000472175800024

الإتاحة: https://doi.org/10.1016/j.jaad.2019.02.053Test
https://hal.umontpellier.fr/hal-02321685Test
https://hal.umontpellier.fr/hal-02321685/documentTest
https://hal.umontpellier.fr/hal-02321685/file/S0190962219303457.pdfTest